People: Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

23 Oct 2020
Change (% chg)

$-0.13 (-3.53%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

MacPhee, John 

Mr. John MacPhee serves as Director of the Company. He has served as a member of our Board of Directors since May 2013 and provided consulting services to us from March 2011 to May 2013, and from February 2016 to December 2016. Since 2011, Mr. MacPhee has served as the Executive Director and CEO of The Jed Foundation, a non-profit organization. From 2005 to 2011, Mr. MacPhee served as Executive Vice President of Par Pharmaceutical, Inc. and President of Par’s Strativa Pharmaceuticals division, where he oversaw commercial operations, clinical development, medical affairs, alliance management, and business development. Previously, Mr. MacPhee worked at Forest Laboratories, Inc., where he led the launches of Celexa, Lexapro, and Namenda. Mr. MacPhee also serves as a board member for Blackthorn Therapeutics, a privately-held pharmaceutical company. Mr. MacPhee holds a B.A. from Columbia College, an M.B.A. from New York University, and an M.P.H. from Columbia University. We believe Mr. MacPhee’s extensive experience building successful specialty pharmaceutical companies and commercializing drug products qualifies him to serve on our Board of Directors.

Basic Compensation

Total Annual Compensation, USD 40,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 27,705
Fiscal Year Total, USD 67,705

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Mahoney


Neil McFarlane


Christopher Prentiss


Adrian Quartel


Vijay Shreedhar


John MacPhee

As Of  31 Dec 2019